

## **BerGenBio ASA: Share capital increase**

**Bergen, Norway, 11 May 2020** - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 4 May 2020 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the private placement and share option program. A total of 13,325,000 shares were issued in the private placement at a subscription price of NOK 37.50 per share and a total of 102,500 share options were exercised and new shares issued at an average subscription price at NOK 11.15 per share.

The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 8,672,580.50 divided into 86,725,805 shares, each with a nominal value of NOK 0.10.

-End-

### Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)

+47 917 86 513

### Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.